Crescent Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	11.88	10.84	-
Revenue Growth	-	-	-
Gross Profit	11.88	10.84	-
Selling, General & Admin	29.45	25.39	12.63
Research & Development	152.67	138.09	56.14
Operating Expenses	182.12	163.48	68.76
Operating Income	-170.24	-152.63	-68.76
Interest Expense	-	-2.19	-3.41
Interest & Investment Income	5.35	2.88	0.7
Pretax Income	-163.12	-151.94	-71.47
Income Tax Expense	2	2	-
Net Income	-165.12	-153.94	-71.47
Net Income to Common	-165.12	-153.94	-71.47
Net Income Growth	-	-	-
Shares Outstanding (Basic)	27	12	1
Shares Outstanding (Diluted)	27	12	1
Shares Change	-	1465.00%	-
EPS (Basic)	-6.03	-12.81	-93.11
EPS (Diluted)	-6.03	-12.81	-93.11
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-73.62	-72.45	-25.08
Free Cash Flow Per Share	-2.69	-6.03	-32.67
Gross Margin	100.00%	100.00%	-
Operating Margin	-1432.63%	-1407.53%	-
Profit Margin	-1389.58%	-1419.61%	-
Free Cash Flow Margin	-619.52%	-668.12%	-
EBITDA	-170.03	-152.55	-
D&A For EBITDA	0.21	0.08	-
EBIT	-170.24	-152.63	-68.76

SEC Filings: 10-K · 10-Q